Herb compound eases stroke-linked depression in mice by resetting gut bacteria

Depression is one of the most common complications of stroke, and it is notoriously hard to treat with standard antidepressants in stroke survivors. A new mouse study offers a mechanistic clue as to why: gut bacteria disrupted by stroke appear to help drive the depression, and a compound from a traditional Chinese herb can ease depressive-like behavior largely by fixing those bacteria.

Key takeaways

• Puerarin, a compound from the kudzu root plant Pueraria lobata, reduced depressive-like behavior in mice with a stroke-and-stress model of post-stroke depression (PSD).
• Fecal microbiota transplants (FMT) showed the effect runs through the gut: microbiota from depressed mice caused depression-like behavior in healthy mice, and microbiota from puerarin-treated mice relieved it in depressed mice.
• The compound calmed an inflammation pathway in the brain called the NLRP3/CASPASE-1 inflammasome and repaired a leaky gut lining.
• This is animal-only evidence from a single lab; there is no human data yet, and puerarin is not an approved treatment for depression.

Puerarin eased depressive-like behavior in post-stroke depression mice

Researchers in China found that oral puerarin, the primary active compound in the medicinal plant Pueraria lobata (kudzu root), reduced depressive-like behavior in mice with post-stroke depression (PSD), a combined stroke-and-chronic-stress model, and that this effect was mediated by the gut microbiota, according to a study published in Frontiers in Microbiology. The team, led by Yu-ting Lu and colleagues at Jinan University, built the PSD model by injecting a stroke-inducing agent into one side of the mice's brains and then subjecting them to three weeks of chronic restraint stress, then measured mood-related behavior with standard rodent tests: how much diluted sugar water a mouse chooses to drink (a proxy for the human symptom of losing interest in pleasurable things), how long it stays still when suspended by its tail or forced to swim (a proxy for behavioral despair), and how freely it explores an open space (a proxy for anxiety).

Post-stroke depression affects roughly a third of stroke survivors

Post-stroke depression (PSD) is estimated to affect somewhere between about a quarter and well over half of stroke survivors within the first few years after their stroke, according to research summarized in a 2025 review in Nutrients & Diet, and it is linked to worse cognitive recovery and higher mortality. Standard antidepressants do not always work well in this population, and experts still disagree on the best treatment approach, according to a review of PSD pathophysiology and drug treatments. For anyone who has watched a stroke survivor's mood decline in ways that feel disconnected from their physical recovery, this study adds to a growing body of evidence that the gut, not just the brain, may be a driver worth targeting.

Two experiments and 90 mice established the gut microbiota's causal role

The study used two linked experiments in a total of 90 male mice. In the first (50 mice), animals with the PSD model were treated for 21 days with a low or high dose of puerarin, a comparison antidepressant (fluoxetine), or a placebo, alongside untreated controls. The low dose of puerarin, 50 mg per kilogram of body weight, produced the most consistent improvement across the behavioral tests, doing about as well as fluoxetine in several measures.

The second experiment (40 mice) is what makes the gut-microbiota claim more than a correlation. The researchers performed a fecal microbiota transplant (FMT), transferring fecal bacteria between mice by gavage to directly swap gut communities. Transplanting stool from untreated PSD mice into otherwise healthy mice was enough to reproduce depressive-like behavior in the recipients. Conversely, transplanting stool from puerarin-treated mice into PSD mice significantly relieved their depressive-like behavior, without those recipient mice ever receiving puerarin themselves. That bidirectional swap is the strongest piece of evidence in the paper: it shows the microbiota itself, not just puerarin acting directly on the brain, can carry the effect in both directions.

What the finding means if you or a loved one is dealing with post-stroke depression

For someone managing depression after a stroke, either their own or a family member's, this study is not a green light to try puerarin or kudzu supplements: it has not been tested in humans for this purpose, dosing safety and drug interactions (including with stroke medications) are unestablished, and "traditional herb" does not mean "proven safe." What it does support is a concrete biological story that a clinician or researcher could eventually test in people: gut bacteria disrupted after stroke may promote a leaky intestinal barrier and activate a specific inflammation pathway in the brain, both of which the study ties to worsened mood symptoms. The researchers found that puerarin repaired the intestinal lining, raising two tight-junction proteins called occludin and ZO-1 that keep the gut wall sealed, and lowered inflammatory markers (IL-1β, IL-6, TNF-α) in the hippocampus and blood while raising the anti-inflammatory marker IL-10. It also suppressed a brain immune-signaling structure called the NLRP3/CASPASE-1 inflammasome (a protein complex that, when overactive, drives inflammation linked to depression and anxiety), which network-pharmacology analysis flagged as a likely target shared by puerarin, depression, and stroke pathways.

The study is animal-only, from one lab, with moderate group sizes

This is a mouse study, not a human trial, and the caveats are significant. Each treatment group held about 10 animals, a workable but modest sample for behavioral testing, and the whole body of evidence comes from a single research group's PSD model, which has not been independently replicated by other labs. Mouse depression models are also an approximation of human depression, not a direct stand-in for it. Puerarin's own bioavailability depends partly on gut bacteria breaking it down into active metabolites, which adds another layer of complexity when trying to extrapolate dosing to people. No human trial of puerarin for post-stroke depression currently exists.

What comes next for this research

The obvious next steps are human validation: does gut microbiota composition after stroke predict who develops depression, and would restoring a healthy microbiota, whether through a compound like puerarin, diet, or an approved FMT protocol, actually help human patients. The Frontiers in Psychiatry meta-analysis of FMT trials for depression in general (non-stroke) populations found some clinical benefit, which suggests this mechanism is worth pursuing beyond mice, but a dedicated PSD trial would be needed to know whether puerarin itself, rather than the broader concept of microbiota restoration, has any role.

Common Questions

Is puerarin safe to take for depression? Not established. This study never tested puerarin in humans, and there is no clinical guidance on dosing or safety for treating depression, including post-stroke depression.

What is the NLRP3/CASPASE-1 inflammasome? It is a protein complex inside cells that, once assembled, triggers inflammation. Chronic overactivation of this pathway in the brain has been linked to depression and anxiety in prior research, and this study found puerarin suppressed it in the hippocampus of depressed mice.

Does this mean gut bacteria cause depression after stroke? The fecal transplant results support a causal role for gut bacteria in this mouse model specifically: transplanting stool from depressed mice induced depression-like behavior in healthy recipients. That is strong evidence for a causal link in mice, but it has not been confirmed in humans.

Could probiotics or diet changes help post-stroke depression in people? This study did not test diet or over-the-counter probiotics, only a specific isolated compound and a controlled fecal transplant. Anyone considering dietary changes for mood after a stroke should discuss it with their treating physician rather than self-treat based on this animal research.

References

1. Yu-ting Lu, Yue-yue Chen, Na-na Ding, et al. (2026). Dual modulation of the NLRP3/CASPASE-1 inflammasome pathway and gut microbial metabolism: the antidepressant mechanism of puerarin. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2026.1907120
2. Mengyue Shen, Penglong Yu, Qian Xiong, Zhongli Sun, Yunhui Zhang, Menglin Yang (2025). Research Advances in Multimodal Framework-Based Identification and Therapeutic Management of Post-Stroke Depression via the Microbiota-Gut-Brain Axis. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s564175
3. Dmitry Frank, Benjamin F. Gruenbaum, Alexander Zlotnik, Michael Semyonov, Amit Frenkel, Matthew Boyko (2022). Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232315114
4. Xiaotao Zhang, Ying Li, Yueyue Guo, Jia Sun, Yang Yang (2025). Clinical efficacy of fecal microbiota transplantation in alleviating depressive symptoms: a meta-analysis of randomized trials. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2025.1656969